Abstract: Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.

Abstract: A system of deep learning neural network in prostate cancer bone metastasis identification based on whole body bone scan images includes a pre-processing module for receiving input whole body bone scan images, and a neural network module for detecting whether there is a prostate cancer bone metastasis. The neural network module includes: a chest portion network module for establishing first stage faster R-CNN and segmenting training images of chest portion according to the input whole body bone scan images, and using the training images to train second stage faster R-CNN and categorizing the lesions of cancerous bone metastasis; and a pelvis portion network module for establishing first stage faster R-CNN and segmenting training images of pelvis portion according to the input whole body bone scan images, and using the training images to train the convolutional neural network to categorize whether it is a bone metastasis image.

Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: A perineal prostate biopsy apparatus comprising a cannula for reaching a prostate gland of an adult human male through his perineum; and a coaxial needle comprising a hollow needle shaft having an open piercing tip at its distal end and being arranged to lie within the cannula so that the piercing tip protrudes from a distal end of the cannula; and, a stylet adapted to lie within the hollow needle shaft so that a distal tip of the stylet closes the piercing tip of the needle.

Abstract: A surgical polygonal locking screw removal device includes: a body including a passage part in which a passage having a preset diameter is formed, and a polygonal expansion part configured to be coupled to a polygonal groove formed in a surgical locking screw to remove the surgical locking screw, the polygonal expansion part protruding from a leading end of the passage part; and a handle configured to be inserted into a rear end of the passage part and screw-coupled to the passage part, and configured to expand the polygonal expansion part.

Abstract: Techniques are provided that involve employing artificial intelligence (AI) to facilitate reducing adverse outcomes associated with healthcare delivery. In one embodiment, a computer implemented method comprises monitoring live feedback received over a course of care of a patient, wherein the live feedback comprises physiological information regarding a physiological state of the patient. The method further comprises employing AI to identify, based on the live feedback information, an event or condition associated with the course of care of the patient that warrants clinical attention or a clinical response. The method further comprises generating a response, based on the identification of the event or condition, that facilitates reducing an adverse outcome of the course of care, wherein the response varies based on a type of the event or condition, and providing the response to a device associated with an entity involved with treating the patient in association with the course of care.

Abstract: The present disclosure relates to a simple, fast, and low cost method for 3D microvascular imaging, termed “scatter labeled imaging of microvasculature in excised tissue” (SLIME). The method can include perfusing a contrast agent through vasculature of a tissue sample with a contrast perfusing unit (22). The contrast agent can include colloids and a dispersant. After the contrast agent is perfused through the vasculature, the vasculature of the tissue sample can be treated with a cross-linking agent delivery unit (24) providing a molecule that cross links with at least a portion of the dispersant to form a sticky, non-Newtonian polymer that prevents leakage of the contrast agent out of the vasculature of the tissue sample. The tissue sample can then be immersed in a solution comprising a clearing agent with an optical clearing unit (26) and subsequently imaged.

Abstract: This disclosure relates to LN02M binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS. In some embodiments, this disclosure provides a binding agent(s) comprising a variable region shown in FIGS. 6A through 6E; amino acid sequence of any mutant of FIGS. 7A through 7D and/or FIGS. 8A through 8F, and any effective (e.g., HIV neutralization) combination thereof; any one or more of SEQ ID NOS. 3-92, 95-233, 248-482, or 491-699; and/or combinations thereof.

Abstract: The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.

Abstract: An atrial fibrillation prediction system is provided. The atrial fibrillation prediction system includes an electrocardiogram obtaining unit and a non-transitory machine-readable medium. The non-transitory machine-readable medium is configured for storing a program which is executed by a processing unit to obtain a prediction result. The program includes a reference database obtaining module, a reference feature selecting module, a training module, a target feature selecting module and a comparing module.

Abstract: The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

Abstract: Methods and systems including a set of interacting nucleic acid structures for use in detecting and/or identifying a target comprising: a nucleic acid sequence capable of being conjugated to a moiety directed to the target; and a nucleic acid nanostructure comprising a segment sequence complementary to a portion of the nucleic acid sequence capable of being conjugated to a moiety directed to the target. The moiety directed to the target may be an antibody, and the nucleic acid nanostructure may be a tetrahedron.

Abstract: A method is provided for determining pulmonary embolism and/or increased risk thereof in a human being, comprising collecting a sample of exhalation air from said human being and determining the presence or absence in said exhaled air of one or more biomarkers associated with pulmonary embolism. Additionally, a kit that comprises the means for detecting at least one biomarker associated with pulmonary embolism or risk thereof is provided.

Abstract: The disclosure relates to an airway maintenance device, such as an endotracheal tube, tracheostomy tube, or supraglottic airway device, and in particular to an airway maintenance device having a sensor for measuring capillary blood flow and/or pressure. The device includes an airway maintenance device with an airway lumen having a proximal end and a distal end, a distal end portion incorporating an optical sensor configured to measure capillary blood flow in tissue surrounding the distal end when in position within a patient's airway. The optical sensor may include a portion of an optical fibre extending to the distal end portion along the lumen.

Abstract: The present invention relates to a biomarker composition for diagnosing and predicting prognosis of prostate cancer, and that the detection rate and expression level of gene combination composed with AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule) in blood tumor cells (CTC) isolated from patients, Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients is related to the level of malignancy in prostate cancer is confirmed and thus the gene combination provides as a biomarker for prostate cancer diagnosis and a biomarker for prognosis prediction of prostate cancer.

Abstract: The present invention pertains to use of sodium diacetate (NaHAc2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product, and a method of treating an infected wound.

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

Abstract: Provided is a medical implant including: an implant base having a surface made of a silicon material; a linker having one end attached onto the surface of the implant base; and a cytokine bound to another end of the linker. By inducing the secretion of anti-inflammatory cytokines, a capsular contracture, which is one of the complications that may occur after transplantation of the patient's breast implant, may occur less.

Abstract: A wound dressing patch includes a backing film; an absorbent foam pad coupled to the a portion of one surface of the backing film; an adhesive sheet provided on a remaining portion of the one surface of the backing film; and a lining material provided along a peripheral edge portion of the adhesive sheet and configured to impart a predetermined stiffness to the backing film. The lining material is spaced apart from the absorbent foam pad to surround the absorbent foam pad in a form of a substantially closed curve along the peripheral edge portion of the adhesive sheet, and a distance between the lining material and an end of the adhesive sheet is shorter than a distance between the lining material and an edge of the absorbent foam pad.

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.